TrialResults-center.org

Menu

Selumetinib MEK inhibitor

Melanoma

All type of patients: 2 trials - Kirkwood - Kirkwood

selumetinib vs temozolomide

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
objective response (ORR)	no data
aaa	no data
recurrence free survival	no data
death (overall survival)	no data
progression or death (progression free survival PFS)	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -